Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and klotho expression

American Journal of Transplantation

Volumn 11, Issue 8, 2011, Pages 1656-1664

  Tataranni, T ^a   Biondi, G ^a   Cariello, M ^a   Mangino, M ^a   Colucci, G ^a   Rutigliano, M ^b   Ditonno, P ^b   Schena, F P ^a   Gesualdo, L ^a   Grandaliano, G ^c  

^a Nephrology Unit   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Ageing; insulin resistance; kidney transplantation; rapamycin

Indexed keywords

CYCLOSPORIN; KLOTHO PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATE; PROTEIN KINASE B; PROTEIN MTORC2; RAPAMYCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; GENE ACTIVATION; HOMEOSTASIS; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; INSULIN RESISTANCE; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GLUCURONIDASE; HUMANS; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE AGENTS; INSULIN RESISTANCE; MALE; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 79961026108     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03590.x     Document Type: Article

References (37)

1. Tsang CK, Qi H, Liu LF, Zheng XF,. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Disc Today 2007; 12: 3-4.
2. Yang Q, Guan KL,. Expanding mTOR signalling. Cell Res 2007; 17: 666-681.
3. Clancy DJ, Gems D, Harshman LG, et al,. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 2001; 292: 104-106. (Pubitemid 32289136)
4. Morris JZ, Tissenbaum HA, Ruvkun G,. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 1996; 382: 536-539. (Pubitemid 26260694)
5. Bartke A, Brown-Borg H,. Life extension in the dwarf mouse. Top Dev Biol 2004; 63: 189-225. (Pubitemid 39752388)
6. Powers RW 3rd, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S,. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev 2006; 20: 174-184. (Pubitemid 43112936)
7. Soukas AA, Kane EA, Carr CE, Melo JA, Ruvkun G,. Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. Genes Dev 2009; 23: 496-511.
8. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S,. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 2004; 14: 885-890. (Pubitemid 38800910)
9. Harrison DE, Strong R, Sharp ZD, et al,. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-395.
10. Selman C, Tullet JMA, Weiser D, et al,. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326: 140-143.
11. Kurosu H, Yamamoto M, Clark JD, et al,. Suppression of aging in mice by the hormone Klotho. Science 2005; 309: 1829-1833. (Pubitemid 41325087)
12. Urakawa I, Yamazaki Y, Shimada T, et al,. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774. (Pubitemid 44949607)
13. Segawa H, Yamanaka S, Ohno Y, et al,. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in Klotho mice. Am J Physiol Renal Physiol 2007; 292: F769-F779. (Pubitemid 46220545)
14. Kuro-o M,. Klotho. Eur J Physiol 2009; 459: 333-343.
15. Utsugi T, Ohno T, Ohyama Y, et al,. Decreased insulin production and increased insulin sensitivity in the Klotho mutant mouse, a novel animal model for human aging. Metabolism 2000; 49: 1118-1123.
16. Schwarz C, Böhmig GA, Steininger R, Mayer G, Oberbauer R,. Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression. Nephrol Dial Transplant 2001; 16: 378-382. (Pubitemid 32123930)
17. Kempe DS, Dërmaku-Sopjani M, Fröhlich H, et al,. Rapamycin-induced phosphaturia. Nephrol Dial Transplant 2010; 25: 2938-2944.
18. Vodenik B, Rovira J, Campistol JM,. Mammalian target of rapamycin and diabetes: What does the current evidence tell us? Transplant Proc 2009; 41: S31-S38.
19. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF,. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? J Am Soc Nephrol 2006; 17: 2236-2244. (Pubitemid 44141914)
20. Walton RJ, Bijowoet OL,. Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975; 2: 309-310.
21. Rosenbaum RW, Hruska KA, Korkor A, Anderson C, Slatopolsky E,. Decreased phosphate reabsorption after renal transplantation: Evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int 1981; 19: 568-578. (Pubitemid 11120903)
22. Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M,. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation 2008; 17: 163-168.
23. Dusso AS, Brown AJ, Slatopolsky E,. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28. (Pubitemid 40863568)
24. Kuro-o M,. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006; 15: 437-441.
25. Quarles LD,. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003; 285: E1-E9. (Pubitemid 36736355)
26. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ,. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60: 2079-2086. (Pubitemid 33070451)
27. Green J, Debby H, Lederer E, Levi M, Zajicek HK, Bick T,. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int 2001; 60: 1182-1196. (Pubitemid 34205819)
28. Han DH, Piao SG, Song JH, et al,. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. Transplantation 2010; 90: 135-141.
29. Dormond O, Madsen JC, Briscoe DM,. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 2007; 282: 23679-23686. (Pubitemid 47311969)
30. Sarbassov DD, Ali SM, Sengupta S, et al,. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168.
31. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY,. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008; 68: 7409-7418.
32. Hu MC, Shi M, Zhang J, et al,. Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24: 3438-3450.
33. Jin H, Xu CX, Lim HT, et al,. High dietary inorganic phosphate increases lung tumorigenesis and alters Akt signaling. Am J Respir Crit Care Med 2009; 179: 59-68.
34. Pavlakis M, Goldfarb-Rumyantzev AS,. Diabetes after transplantation and sirolimus: What's the connection? J Am Soc Nephrol 2008; 19: 1255-1256.
35. Teutonico A, Schena FP, Di Paolo S,. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128-3135. (Pubitemid 44743511)
36. Johnston O, Rose CL, Webster AC, Gill JS,. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418.
37. Romagnoli J, Citterio F, Nanni G, et al,. Incidence of post-transplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 2006; 38: 1034-1036. (Pubitemid 43815926)